Sudhanshu Kalantri

Sudhanshu Kalantri

Auto-generated profile, based on publicly available information

Sudhanshu Kalantri

Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s NMIMS-Deemed to be University, Mumbai, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
SKSudhanshu Kalantri
Sudhanshu Kalantri
AVAmisha Kamlesh Vora
Amisha Kamlesh Vora
Objective TheDES are formed by mixing a Hydrogen Bond Donor (HBD) and a Hydrogen Bond Acceptor (HBA) in appropriate molar ratios. These solvents have been shown to enhance drug solubility, permeability, and delivery. The main objective of the present article is to review these advantages of TheDES. TheDES show unique properties, such as low toxicity, biodegradability, improved bioavailability and enhanced drug delivery of poorly soluble active pharmaceutical ingredients. They are also biocompatible in nature which makes them a promising candidate for various therapeutic applications, including drug formulations, drug delivery and other biomedical uses. The development and utilization of TheDES shows significant advancement in pharmaceutical research, providing new opportunities for improving drug delivery. The current study was carried out by conducting a systematic literature review that identified relevant papers from indexed databases. Numerous studies and research are cited and quoted in this article to demonstrate the effectiveness of TheDES in enhancing drug solubility, permeability, and delivery. All chosen articles were selected considering their significance, quality, and approach to addressing issues. As a result, various TheDES were identified that can be formulated in different ways: one component can act as a vehicle for an API, either HBD or HBA can be an API, both HBD and HBA can be APIs, or the individual components of DES are not therapeutically active but the resulting DES possesses therapeutic activity. Additionally, TheDES were also recognized to enhance drug delivery and solubility for different APIs, including NSAIDs, anesthetic drugs, antifungals, and others.

4 October 2025 in Discover Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
SKSudhanshu Kalantri
Sudhanshu Kalantri
ANAnuj N. Nahata
Anuj N. Nahata
NGNandan Godani
Nandan Godani
In recent years, microneedle (MN) and biosensor technologies have emerged as innovative solutions for non-invasive drug delivery and real-time disease diagnostics. Microneedles offer numerous advantages, including minimal pain, targeted delivery, improved bioavailability, and enhanced patient compliance. Various types—solid, hollow, dissolving, coated, and hydrogel microneedles—are designed to address specific therapeutic needs, each with unique drug release mechanisms. Advanced fabrication techniques such as 3D printing, laser ablation, photolithography, and micro-stereolithography allow for precise design and scalability. Biosensors, composed of bioreceptors and transducers, detect and quantify biological signals with high sensitivity and specificity. These devices are classified based on bioreceptors (enzymes, antibodies, cells), transduction mechanisms (electrochemical, optical, acoustic), and detection principles (mechanical, electronic). The integration of microneedles with biosensors enables continuous, real-time monitoring of biomarkers for chronic diseases such as diabetes, cancer, neurological disorders like Parkinson’s disease, and renal dysfunction. Several microneedle-based biosensing devices have been developed for glucose, urea, cholesterol, nitric oxide, and carcinoembryonic antigen detection. Powering these biosensors effectively remains crucial. Emerging technologies such as triboelectric, piezoelectric, thermoelectric nanogenerators, and biological fuel cells offer promising self-powered solutions. Moreover, the future scope includes integration with artificial intelligence (AI), Internet of Things (IoT), and biodegradable materials for personalized and sustainable healthcare. This review highlights the synergistic potential of microneedles and biosensors in diagnostics and therapeutics, emphasizing their role in transforming point-of-care medicine and wearable health monitoring. Graphical abstract